Compare LBRX & FLNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LBRX | FLNG |
|---|---|---|
| Founded | 2015 | 2006 |
| Country | United States | Bermuda |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Marine Transportation |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.7B |
| IPO Year | 2025 | 2019 |
| Metric | LBRX | FLNG |
|---|---|---|
| Price | $47.00 | $31.29 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 5 | 1 |
| Target Price | ★ $46.60 | $23.00 |
| AVG Volume (30 Days) | 285.4K | ★ 393.9K |
| Earning Date | 05-06-2026 | 05-13-2026 |
| Dividend Yield | N/A | ★ 9.40% |
| EPS Growth | ★ 98.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $2.14 |
| P/E Ratio | ★ N/A | $19.72 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.40 | $24.00 |
| 52 Week High | $50.16 | $33.40 |
| Indicator | LBRX | FLNG |
|---|---|---|
| Relative Strength Index (RSI) | 56.39 | 49.92 |
| Support Level | $21.90 | $30.38 |
| Resistance Level | $49.65 | $31.31 |
| Average True Range (ATR) | 2.02 | 0.83 |
| MACD | -0.53 | -0.02 |
| Stochastic Oscillator | 30.43 | 26.39 |
LB Pharmaceuticals Inc is a late-stage biopharmaceutical company developing novel therapies for the treatment of a wide range of neuropsychiatric disorders including schizophrenia, bipolar depression, adjunctive treatment of depressive disorder and other diseases. It is building a pipeline that leverages the broad therapeutic potential of its product candidate, LB-102, which it believes has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is currently in late-stage clinical development for schizophrenia and bipolar depression. The company operates as a single reportable segment in the development of novel therapies for the treatment of neuropsychiatric diseases, including schizophrenia.
Flex LNG Ltd is an LNG shipping company with a fleet of next-generation LNG carriers with large cargo capacity. The company's fleet consists of several LNG carriers on the water, and all of its vessels are of the latest generation equipped with two-stroke propulsion. Its fleet consists of M-type, Electronically Controlled, Gas Injection (MEGI) LNG carriers and Generation X Dual Fuel (X-DF) LNG carriers, offering improvements in fuel efficiency and thus also carbon footprint compared to the older steam and four-stroke propelled ships. The company has one reportable segment: vessel operations, which generates revenue from the chartering of vessels to customers.